Rosetta Genomics Says ‘Technical Obstacles’ Will Delay Colorectal Cancer Screen Launch

Rosetta also said that CEO Amir Avniel intends to step down in order to take the reins of Rosetta’s roughly year-old plant biotechnology unit, Rosetta Green. The disclosures were made as the company reported its second-quarter financial results.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.